Cytiva Opens New Manufacturing Facility in Massachusetts
Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.
Cytiva opened its new 80,000-ft2 manufacturing facility in Shrewsbury, MA, the company announced in a Dec. 21, 2020 press release. The new facility will make Xcellerex XDR single-use bioreactors and is part of Cytiva’s $500 million global capacity expansion planned for the next five years. The Shrewsbury site expansion was supported by a Technology Investment Agreement entered in October with the US Biomedical Advanced Research and Development Authority (BARDA).
The new facility was built in less than five months to meet demand for the company’s technologies. The building includes five manufacturing lines operating 24/5, a new cleanroom, and an R&D lab. The company is also adding manufacturing lines for complementary single-use technologies at its Westborough, MA facility and expects the capacity expansion to be completed by Q2 2021.
Source: Cytiva
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
